Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNA
May 14, 2021 07:00 ET
|
Dyne Therapeutics, Inc.
- Robust Reduction in DMPK RNA in Multiple Muscles at Four Weeks in Novel In Vivo Model Developed by Dyne; Additional In Vitro Data Support Advancement of Lead DM1 Candidate - - DM1 Program One of...
Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
May 06, 2021 07:29 ET
|
Dyne Therapeutics, Inc.
- On Track to Submit INDs for DM1, DMD and FSHD Programs Between the Fourth Quarter of 2021 and the Fourth Quarter of 2022 - - Well-Resourced with Cash Runway Expected into the Second Half of 2024 - ...
New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting
April 27, 2021 16:35 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
March 04, 2021 07:35 ET
|
Dyne Therapeutics, Inc.
- Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 - - Recent Appointments to Experienced Leadership Team...
Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer
March 04, 2021 07:25 ET
|
Dyne Therapeutics, Inc.
Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy in Neuromuscular Disease WALTHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) --...
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
February 08, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease WALTHAM, Mass., Feb. 08, 2021 (GLOBE...
Dyne Therapeutics Announces Pricing of $168 Million Public Offering
January 20, 2021 20:05 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
January 10, 2021 15:00 ET
|
Dyne Therapeutics, Inc.
- In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 - - Preclinical Data Further Validate FORCE™ Platform; IND Submissions Planned for DM1, DMD and FSHD...
Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics to Present at Upcoming Investor Conferences
November 09, 2020 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...